Trevi Therapeutics Inc. (TRVI) Statistics & Valuation Metrics - Stocknear

Trevi Therapeutics Inc.

NASDAQ: TRVI · Real-Time Price · USD
7.01
-0.22 (-3.04%)
At close: Sep 05, 2025, 3:59 PM
7.01
0.00%
After-hours: Sep 05, 2025, 07:03 PM EDT

Trevi Therapeutics Statistics

Share Statistics

Trevi Therapeutics has 121.78M shares outstanding. The number of shares has increased by 64.13% in one year.

121.78M
64.13%
23.23%
74.57%
80.73M
17,776
0.97%

Short Selling Information

The latest short interest is 10.11M, so 8.3% of the outstanding shares have been sold short.

10.11M
8.3%
9.62%
7.54

Valuation Ratios

The PE ratio is -8.69 and the forward PE ratio is -14.46. Trevi Therapeutics's PEG ratio is -0.14.

-8.69
-14.46
0
777.6
4.18
-10.87
-0.14
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Trevi Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 10.41, with a Debt / Equity ratio of 0.01.

10.41
10.41
0.01
-0.02
-0.03
-12881

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.55M
31
0
n/a

Taxes

-30K
0.06%

Stock Price Statistics

The stock price has increased by 137.63% in the last 52 weeks. The beta is 0.72, so Trevi Therapeutics's price volatility has been higher than the market average.

0.72
137.63%
7.03
5.55
44.02
1,838,969

Income Statement

n/a
-147K
-51.52M
-47.91M
-47.79M
-47.94M
-0.47
Full Income Statement

Balance Sheet

The company has 34.1M in cash and 1.03M in debt, giving a net cash position of 33.06M.

34.1M
1.03M
33.06M
-287.05M
208.34M
197.99M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -38.26M and capital expenditures -35K, giving a free cash flow of -38.29M.

-38.26M
-35K
-38.29M
-0.38
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

TRVI does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for TRVI is $21, which is 199.6% higher than the current price. The consensus rating is "Buy".

$21
199.6%
Buy
9
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

53.56
2